Covid-19 Treatment: The World Health Organization has announced to start an international trial of three drugs to find out whether they improve the condition of hospitalized Covid patients. Artesunate, Imatinib (imatinib) and Infliximab (infliximab) will be tested on volunteer patients in more than 600 hospitals in 52 countries.
On August 11, Tedros Adhanom Ghebreyesus, the head of the health agency, said, “The need of the hour is to find more effective and accessible treatment for patients with Covid-19.” Artesunate is used to treat severe malaria, imatinib is used to prevent certain types of cancer, and infliximab is used to treat immune system diseases such as joint pain and Crohn’s.
WHO’s big announcement under ‘shared testing’
The World Health Organization says that joint research in dozens of countries will allow trials to reach multiple treatments while staying in one protocol, while also estimating the effect of each drug on patients. In view of the ability to reduce the risk of death in the patients of Covid-19 treated in the hospital, the medicines for the trial have been selected by an independent panel. The manufacturers donated the medicines and have already been delivered to the hospitals that are part of the trial.
The investigation of all three medicines on patients of Covid-19 is part of the second phase of the campaign by the organization to find effective treatment against the corona virus. Earlier, in the first phase of the ‘common trial’, the effect of four medicines was evaluated on 13,000 patients in 500 hospitals in 30 countries. Preliminary results released in October 2020 showed that Remdesivir, hydroxychloroquine, lopinavir and interferon did not benefit COVID-19 patients treated in hospitals.
Trial of 3 medicines will be done against Covid
The results of the first phase of trials are likely to be released in September next month. The organization’s advisory group recommended evaluation because of its anti-inflammatory properties, which has been used for over 30 years in the treatment of malaria and other parasitic diseases and is considered very safe. Human trials on imatinib in the Netherlands showed that it could benefit hospitalized Covid patients. Similarly, infliximab is known to be effective and safe for the prevention of inflammation. In Kovid-19 patients, the risk of complications increases with the increase in the intensity of inflammation.